1. Scrip

First Phase III Success Opens Up Cardiovascular Pathway For Arrowhead

 
• By Andrew McConaghie

Arrowhead could have its first in-house RNA therapy on the market by 2025, with big plans to expand its reach in cardiometabolic disease, following a pivotal trial hit.

Arrowhead

Some twenty years since it was founded, Arrowhead Pharmaceuticals has achieved its first Phase III success from its in-house RNA interference platform.

The company has so far been in the shadow of more advanced companies with RNA-based therapies such as Alnylam and Ionis, but trial results are starting to validate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Tech Convergence, Quality Data Needed To Accelerate Korea’s AI-Powered R&D

 
• By Jung Won Shin

AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.